

**Next Science Limited  
General Meeting  
Wednesday, 18 November 2020**

**Managing Director's Address**

I am pleased to report that the testing required to complete our FDA filing and anticipated approval for our XPerience Surgical Rinse is progressing well.

We have had additional meetings and formal written notification from the FDA for the specific testing requirements and we expect to have the written reports back to the FDA before year end. We have strong confidence that with the submission of these reports we will have then met all of the FDA's requirements for a 510(k) clearance of substantial equivalence leading to product approval and commercial launch in the 1st half of 2021.

The XPerience Surgical Rinse is a landmark growth opportunity for Next Science. XPerience will be by far the most effective product to address Surgical Site infection, a \$15bn per annum global market growing at an estimated 6% per annum.

Next Science's existing products in market, Bactisure, BlastX, SurgX and acne treatments, continue to gain market support.

Revenue run rates in Q4 2020 have now returned to Q4 2019 levels and we are looking forward to 2021 to continue the upwards trajectory with the launch of the XPerience Surgical Rinse.

We continue to broaden our science and expand our patent assets, now with 30 patents granted globally, and we expect to have our 2nd product (BlastX) cleared with a CE Mark by year end.

I would like to take this opportunity to thank the Directors, my fellow colleagues and all of our shareholders for their support for the business and the opportunity to improve substantially patient health.

Approved and authorised by Next Science's Managing Director.

Further information:

**Judith Mitchell**

Managing Director, Next Science Limited  
Phone: +61 2 9375 7989  
Email: [investorqueries@nextscience.com](mailto:investorqueries@nextscience.com)

**Michael Brown**

Pegasus Advisory  
Phone: +61 400 248 080  
Email: [mbrown@pegasusadvisory.com.au](mailto:mbrown@pegasusadvisory.com.au)

**About Next Science**

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology.

Website: [www.nextscience.com](http://www.nextscience.com).